When would you ever consider lifelong imatinib in adjuvant therapy for GIST?

Would non-gastric GISTs, high mitotic rate, large size, and young age of patient affect your decision? Especially knowing that TKIs suppress cell growth rather than eradicate disease

Answer from: Medical Oncologist at Academic Institution

The risk of recurrence and mutational status are important tumor related factors. Combine that with host factors including risk tolerance and physical drug tolerance helps with the conversation to reach a unanimous decision.

Comments

Medical Oncologist at Albert Einstein College of Medicine of Yeshiva University
Would you use lifelong in some cases? Would insura...

Medical Oncologist at University of Virginia
Great question with no good data to guide the deci...

Related Questions